Skip to main content

Table 4 Univariate analyses of factors associated with severe and/or opportunistic infections. Landmark competing risk analysis at 9 months. sHR indicates sub-Hazard Ratio

From: Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

 

Infections

Relapse/death

Variables

sHR [95%CI]

p

sHR [95%CI]

p

EOT MRD status (n = 125)

  < 10−4 (ref)

1.00

 

1.00

 

  ≥ 10−4

0.72 [0.29; 1.82]

0.492

3.02 [1.68; 5.45]

< 0.001

EOT CD4 (/mm3, n = 125)

  ≤ 200 (ref)

1.00

 

1.00

 

  > 200

0.97 [0.40; 2.38]

0.948

2.34 [1.26; 4.33]

0.007

EOT NK (/mm3, n = 119)

  ≤ 100 (ref)

1.00

 

1.00

 

  > 100

0.51 [0.21; 1.22]

0.128

1.07 [0.58; 1.96]

0.837

EOT CD8 (/mm3, n = 125)

  ≤ 150

1.00

 

1.00

 

  > 150

1.84 [0.79; 4.30]

0.158

1.06 [0.59; 1.89]

0.843